Clinicolopathological, Cytogenetic, and Radiographical Analysis of Waldenstrom Macroglobulinemia in Japan: Unique Disease Manifestation


Waldenstr?m macroglobulinemia (WM) is a rare lymphoid malignancy. Many studies, including clinicopathological, cytogenetic, gene expression profile, and therapy studies have been reported from the US and Europe, although only a few reports are available from East Asia, including Japan. To further clarify the clinicopathological, radiological, and cytogenetic features of WM in Japan, we performed a retrospective analysis of WM in our institute between March 2007 and January 2012. Clinical data, laboratory data, the results of flow cytometric analysis (FCM), and chromosomal abnormalities were analyzed, and a radiological review was performed. The treatment regimen, response, and survival were also estimated. Six patients were enrolled in this study. The median age was 71 years. All patients were symptomatic, 3 had hyperviscosity syndrome, 1 had bone lesions, and 1 had an extra-medullary mass. FCM data showed that all patients were positive for CD38, while 2 were positive for CD56. Four had chromosomal abnormalities including some abnormalities also reported in myeloma. On radiological review, four showed diffuse invasion of the retro-peritoneum. Five patients received treatment, 4 of which achieved a response. At a median follow-up of 527 days, 4 were alive and 2 died because of disease progression. The present study revealed that WM in Japan might be heterogeneous and have a unique disease manifestation. Invasion sites other than bone marrow were very common, and the results of clinical, FCM, and cytogenetic studies revealed that WM in Japanese cases might have manifestations of both myeloma and B-cell lymphoma.

Share and Cite:

N. Sekiguch, N. Takezako, M. Wagatsuma, C. Kunihiro, A. Nagata, I. Fukuda, S. Noto, I. Saito, K. Yamada and A. Miwa, "Clinicolopathological, Cytogenetic, and Radiographical Analysis of Waldenstrom Macroglobulinemia in Japan: Unique Disease Manifestation," Journal of Cancer Therapy, Vol. 3 No. 6, 2012, pp. 1037-1044. doi: 10.4236/jct.2012.36134.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] S. H. Swerdlow, F. Berger and S. A. Pikeru, “Lymphoplasmacytic Lymphoma,” In: S. H. Swerdlow, E. Campo, N. L. Harrus, et al., World Health Organization Classification of Tumour of Hematopoietic and Lymphoid Tissues, IARC Press, Lyon, 2007, pp. 194-195.
[2] G. C. Issa, H. Leblebjian and A. M. Roccaro, “New Insights into the Pathogenesis and Treatment of Waldenstrom Macroglobulinemia,” Current Opinion in Hematology, Vol. 18, No. 4, 2011, pp. 260-265. doi:10.1097/MOH.0b013e3283474e5b
[3] M. A. Gertz, “Waldenstrom Macroglobulinemia: 2011 Update on Diagnosis, Risk Stratification, and Management,” American Journal of Hematology, Vol. 86, No. 5, 2011, pp. 411-416. doi:10.1002/ajh.22014
[4] A. Vijay and M. A. Gertez, “Waldenstrom Macroglobulinemia,” Blood, Vol. 109, No. 12, 2007, pp. 5096-5130. doi:10.1182/blood-2006-11-055012
[5] Lymphoma Study Group of Japanese Pathologists, “The World Health Organization Classification of Malignant Lymphomas in Japan: Incidence of Recently Recognized Entities,” Pathology International, Vol. 50, No. 9, 2000, pp. 696-702. doi:10.1046/j.1440-1827.2000.01108.x
[6] M. A. Dimopoulos and A. Anagnostopoulos, “Waldenstrom’s Macroglobulinemia,” Best Practice and Research Clinical Haematology, Vol. 18, No. 4, 2005, pp. 747-765. doi:10.1016/j.beha.2005.01.028
[7] R. L. Sargent, J. R. Cook and N. I. Aguilera, “Fluorescence Immunophenotypic and Interphase Cytogenetic Characterization of Nodal Lymphoplasmacytic Lymphoma,” American Journal of Surgical Pathology, Vol. 32, No. 11, 2008, pp. 1643-1653. doi:10.1097/PAS.0b013e3181758806
[8] R. Banwait, O. Regan and F. Campigotto, “The Role of 18F-FDG PET/CT Imaging in Waldenstrom Macroglobulinemia,” American Journal of Hematology, Vol. 86, No. 7, 2011, pp. 567-572. doi:10.1002/ajh.22044
[9] A. Chiappella, C. Ciochetto and L. Orsucci, “Update in Indolent Non-Hodgkin Lymphoma (NHL): Paradigm for Waldenstrom’s Macroglobulinemia (WM),” Clin Lymphoma Myeloma Leuk, Vol. 11, No. 1, 2011, pp. 149-151. doi:10.3816/CLML.2011.n.035
[10] L. Ioakimidis, C. J. Patterson and Z. R. Hunter, “Comparative Outcomes Following CP-R, CVP-R, and CHOPR in Waldenstrom’s Macroglobulinemia,” Clinical Lymphoma, Myeloma, Vol. 9, No. 1, 2009, pp. 62-66. doi:10.3816/CLM.2009.n.016
[11] C. Buske, E. Hoster and M. Dreyling, “German LowGrade Lymphoma Study Group. The Addition of Rituximab to Front-Line Therapy with CHOP (R-CHOP) Results in a Higher Response Rate and Longer Time to Treatment Failure in Patients with Lymphoplasmacytic Lymphoma: Results of a Randomized Trial of the German Low-Grade Lymphoma Study Group (GLSG),” Leukemia, Vol. 23, No. 1, 2009, pp. 153-161. doi:10.1038/leu.2008.261
[12] S. P. Treon, C. Hanzis and C. Tripsas, “Bendamustine Therapy in Patients with Relapsed or Refractory Waldenstrom’s Macroglobulinemia,” Clinical Lymphoma, Myeloma, and Leukemia, Vol. 11, No. 1, 2011, pp. 133-135. doi:10.3816/CLML.2011.n.030
[13] R. G. Owen, S. P. Treon and A. Al-Katib, “Clinicopathological Definition of Waldenstrom’s Macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia,” Seminers in Oncology, Vol. 30, No. 2, 2003, pp. 110-115.
[14] E. D. Remstein, C. A. Hanson and R. A. Kyle, J. M. Hodnefield and P. J. Kurtinet, “Despite Apparent Morphologic and Immunophenotypic Heterogeneity, Waldenstrom’s Macroglobulinemia Is Consistently Composed of Cells along a Morphologic Continuum of Small Lymphocytes, Plasmacytoid Lymphocytes, and Plasma Cells,” Seminers in Oncology,Vol. 30, No. 2, 2003, pp. 182-186. doi:10.1053/sonc.2003.50073
[15] P. J. Kurtin, K. S. Hobday and S. Ziesmer, “Demonstration of Distinct Antigenic Profiles of Small B-Cell Lymphomas by Paraffin Section Immunohistochemistry,” American Journal of Clinical Pathology, Vol. 112, No. 3, 1999, pp. 319-329.
[16] M. T. Howard, J. Hodnefield and W. G. Morice, “Immunohistochemical Phenotyping of Plasma Cells in Lymphoplasmacytic Lymphoma/Waldenstrom’s Macroglobulinemia Is Comparable to Flow Cytometric Techniques,” Clinical Lymphoma, Myeloma, and Leukemia, Vol. 11, No. 1, 2011, pp. 96-98. doi:10.3816/CLML.2011.n.018
[17] R. F. Schop, W. M. Kuehl and S. A. V. Wier, “Waldenstrom Macroglobulinemia Neoplastic Cells Lack Immunoglobulin Heavy Chain Locus Translocations but Have Frequent 6q Deletions,” Blood, Vol. 100, No. 8, 2002, pp. 2996-3001. doi:10.1182/blood.V100.8.2996
[18] E. Braggio, J. J. Keats and X. Leleu, “High-Resolution Genomic Analysis in Waldenstrom’s Macroglobulinemia Identifies Disease-Specific and Common Abnormalities with Marginal Zone Lymphomas,” Clinical Lymphoma and Myeloma, Vol. 9, No. 1, 2009, pp. 39-42. doi:10.3816/CLM.2009.n.009
[19] R. F. Schop, S. M. Jalal and S. A. V. Wier, “Deletions of 17p13.1 and 13q14 Are Uncommon in Waldenstrom Macroglobulinemia Clonal Cells and Mostly Seen at the Time of Disease Progression,” Cancer Genetics and Cytogenetics, Vol. 132, No. 1, 2002, pp. 55-60. doi:10.1016/S0165-4608(01)00526-X
[20] A. K. Azab, F. Azab and P. Quang, “FGFR3 Is Overexpressed Waldenstrom Macroglobulinemia and Its Inhibition by Dovitinib Induces Apoptosis and Overcomes Stroma-Induced Proliferation,” Clinical Cancer Research, Vol. 17, No. 13, 2011, pp. 4389-4399. doi:10.1158/1078-0432.CCR-10-2772
[21] W. J. Chng, R. Schop and T. Price-Troska, “Gene Expression Profiling of Waldenstrom’s Macroglobulinemia Reveals a Phenotype More Similar to Chronic Lymphocytic Leukemia than Multiple Myeloma,” Blood, Vol. 108, No. 8, 2006, pp. 2755-2763. doi:10.1182/blood-2006-02-005488
[22] N. C. Gutierrez, E. M. Ocio and J. D. L. Rivas, “Gene Expression Profiling of B Lymphocytes and Plasma Cells from Waldenstrom’s Macroglobulinemia: Comparison with Expression Patterns of the Same Cell Counterparts from Chronic Lymphocytic Leukemia, Multiple Myeloma and Normal Individuals,” Leukemia, Vol.21, No. 3, 2007, pp. 541-549. doi:10.1038/sj.leu.2404520
[23] Y. Liu, K. Miyazawa and G. Sashida, “Deletion (20q) as the Sole Abnormality in Waldenstrom Macroglobulinemia Suggests Distinct Pathogenesis of 20q11 Anomaly,” Cancer Genetics and Cytogenetics, Vol. 169, No. 1, 2006, pp. 69-72. doi:10.1016/j.cancergencyto.2006.03.013
[24] N. Kawano, N. Ikeda and S. Yoshida, “Successful Treatment of Cryoglobulinemic Glomerulonephritis Derived from Waldenstrom's Macroglobulinemia by RituximabCHOP and Tandem High-Dose Chemotherapy with Auto-logous Peripheral Blood Stem Cell Transplantation,” International Journal of Hematology, Vol. 92, No. 2, 2010, pp. 391-397. doi:10.1007/s12185-010-0638-1
[25] S. M. Bang, J. W. Seo and K. U. Park, “Molecular Cytogenetic Analysis of Korean Patients with Waldenstrom Macroglobulinemia,” Cancer Genetics and Cytogenetics, Vol. 197, No. 2, 2010, pp. 117-121. doi:10.1016/j.cancergencyto.2009.11.008
[26] Y. M. Won, S. J. Kim and K. Kim, “Clinical Features and Treatment Outcomes of Lymphoplasmacytic Lymphoma: A Single Center Experience in Korea,” Annals of Hematology, Vol. 89, No. 10, 2010, pp. 1011-1018. doi:10.1007/s00277-010-0978-1
[27] Y. Shuhua, C. Lui and L. Zengjun, “Distinct Characteristics of Chinese Patient with Waldenstrom Macroglobuminemia: A Report with 90 Cases from a Single Representative Center,” Proceedings of 7th international Workshop on Waldenstrom’s Macloglobuminemia, Newport, 26 August 2012.
[28] M. M. Oken, R. H. Creech and D. C. Tormey, “Toxicity and Response Criteria of Eastern Cooperative Oncology Group,” American Journal of Clinical Oncology, Vol. 5, No. 6, 1982, pp. 649-655. doi:10.1097/00000421-198212000-00014
[29] Abbott FISH Technology Protocol, 2012.
[30] S. P. Treon, G. Merlini and E. Morra, “Report from the Sixth International Workshop on Waldenstrom’s Macroglobulinemia,” Clinical Lymphoma, Myeloma, and Leukemia, Vol. 11, No. 1, 2011, pp. 69-73.
[31] P. Morel, A. Duhamel and P. Gobbi, “International Prognostic Scoring System for Waldenstrom Macroglobulinemia,” Blood, Vol. 113, No. 18, 2009, pp. 4163-4170. doi:10.1182/blood-2008-08-174961
[32] S. Feyler, S. J. O’Connor and A. C. Rawstron, “IgM Myeloma: A Rare Entity Characterized by a CD20-CD56-CD117-Immunophenotype and the t(11;14),” British Journal of Haematology, Vol. 140, No. 5, 2008, pp. 547-551. doi:10.1111/j.1365-2141.2007.06969.x
[33] S. R. Schuster, S. V. Rajkumar and A. Dispenzieri, “IgM Multiple Myeloma: Disease Definition, Prognosis, and Differentiation from Waldenstrom’s Macroglobulinemia,” American Journal of Hematology, Vol. 85, No. 11, 2010, pp. 853-855. doi:10.1002/ajh.21845
[34] J. R. Sawyer, J. L. Lukacs and N. Munshi, “Identification of New Nonrandom Translocations in Multiple Myeloma with Multicolor Spectral Karyotyping,” Blood, Vol. 92, No. 11, 1998, pp. 4269-4278.
[35] R. E. Tiedemann, N. Gonzalez Paz and R. A. Kyle, “Genetic Aberrations and Survival in Plasma Cell Leukemia,” Leukemia, Vol. 22, No. 5, 2008, pp. 1044-1052. doi:10.1038/leu.2008.4
[36] N. V. Smadja, D. Leroux and J. Soulier, “Further Cytogenetic Characterization of Multiple Myeloma Confirms That 14q32 Translocations Are a Very Rare Event in Hyperdiploid Cases,” Genes, Chromosomes & Cancer , Vol. 38, No. 3, 2003, pp. 234-239. doi:10.1002/gcc.10275
[37] A. S. T. Lim, T. J. Chen and T. H. Lim, “Bone Marrow Cytogenetics Workup: Application of Lean Management System to Determine if Additional Cell Workup Is Helpful and Necessary to Analysis,” Annals Academy of Medicine Singapore, Vol. 39, No. 9, 2010, pp. 696-704.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.